In the phase IIa study, the primary endpoint was an expected improvement in AQLQ compared to placebo and the secondary endpoints incorporated measures of asthma control.
“The profile and magnitude of the placebo response is extremely surprising and merits further examination,” said Dr Kevin Mullane, CEO and president of Inflazyme Pharmaceuticals.
“We are currently conducting a validation review process of the full trial. We expect to report on the outcome of this within the next two to three weeks.”
The company is also expecting to report this quarter on the results of IPL455,903, a non-emetic PDE4 inhibitor which is currently being tested in a phase IIa clinical study in age-associated memory impairment.